Universität zu Köln

Stauder, R., Eichhorst, B., Hamaker, M. E., Kaplanov, K., Morrison, V. A., Osterborg, A., Poddubnaya, I., Woyach, J. A., Shanafelt, T., Smolej, L., Ysebaert, L. and Goede, V. (2017). Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann. Oncol., 28 (2). S. 218 - 228. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Full text not available from this repository.

Abstract

Chronic lymphocytic leukemia (CLL) mainly affects older people: the median age at diagnosis is> 70 years. Elderly patients with CLL are heterogeneous with regard both to the biology of their disease and aging. Following the diagnosis of CLL in an elderly individual, careful risk assessment is essential when treatment options are evaluated. This includes not only clinical staging and evaluation of disease-specific prognostic biomarkers such as 17p deletion and TP53 mutation, but also of comorbidities, physical capacity, nutritional status, cognitive capacity, ability to perform activities of daily living and social support. Comorbidity scoring and geriatric assessment tools are helpful in achieving such multidimensional evaluation in a systematic manner. The introduction of new drugs including novel monoclonal antibodies and kinase inhibitors offers enhanced opportunities for the treatment of elderly patients with CLL. This position paper of a Task Force of the International Society of Geriatric Oncology (SIOG) reviews currently available evidence relevant to such patients. All types of elderly patient (i. e. chronological age> 65-70 years) are considered, from robust (fit) to vulnerable (unfit) to the terminally ill. Among the topics covered are the following: (i) the relationship between chronological age, prognosis and survival, (ii) assessment of biological aging, (iii) biological age as a determinant of treatment feasibility and tolerance and (iv) tailoring of both first and further-line treatment to the circumstances of the individual patient.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Stauder, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichhorst, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hamaker, M. E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kaplanov, K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Morrison, V. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Osterborg, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Poddubnaya, I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Woyach, J. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Shanafelt, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Smolej, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ysebaert, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Goede, V. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-241494
DOI:	10.1093/annonc/mdw547
Journal or Publication Title:	Ann. Oncol.
Volume:	28
Number:	2
Page Range:	S. 218 - 228
Date:	2017
Publisher:	OXFORD UNIV PRESS
Place of Publication:	OXFORD
ISSN:	1569-8041
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PREVIOUSLY UNTREATED PATIENTS; OLDER PATIENTS; INITIAL THERAPY; RITUXIMAB REGIMEN; PLUS CHLORAMBUCIL; CLINICAL-TRIALS; CANCER-PATIENTS; OPEN-LABEL; CHEMOTHERAPY TOXICITY; PROGNOSTIC MARKERS Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24149